15 October 2015 - Below is a list of forthcoming submissions that have recently been added to the SMC's programme.

• Adalimumab (Humira)
• Bevacizumab (Avastin)
• Eculizumab (Soliris)
• Elvitegravir with cobicistat and emtricitabine and tenofovir alafenamide fumarate (Genvoya)
• Eribulin mesylate (Halaven)
• Insulin detemir (Levemir)
• Ivacaftor (Kalydeco)
• Nivolumab (Nivolumab BMS)
• Oseltamivir phosphate (Tamiflu)
• Sacubitril with valsartan (Entresto)

For more details, go to: http://www.scottishmedicines.org.uk/SMC_Advice/Forthcoming_Submissions/Forthcoming_Submissions?iru=2ICSSBDQBC